Subscribe To

Price Alert Latest News Economic Calendar News

ZYNE / Zynerba Pharmaceuticals appoints Albert Parker as its new chief legal officer upon retirement of Suzanne Hanlon at end-February

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced the appointment of Albert P Parker as the company's new chief legal officer and corporate secretary. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, will assume the duties of Suzanne Hanlon, who will retire from her position at the end of February 2022, the company said. Read More

Demo Live Account See Partner Details

Content Topics

Zynerba

Pharmaceuticals

Appoints

Albert

Parker

Chief

Legal

Officer

Retirement

Suzanne

Hanlon

End february

Stock

ZYNE

Posted: Feb 15 2022, 08:20

Author Name: Proactive Investors

ZYNE News

By InvestorPlace
August 14, 2023

Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?

In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ: ZYNE ) skyrocketed on Monday followi

By Proactive Investors
August 14, 2023

Zynerba Pharma stock rockets on premium priced Harmony deal

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock rocketed three-times higher as investors are set to pocket a bumper payday as Harmony Biosciences (NAS

By Zacks Investment Research
June 29, 2023

Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?

Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st

By GlobeNewsWire
June 20, 2023

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transde

By Zacks Investment Research
January 9, 2023

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try a different approach? Tap five stocks with increasing P/E ratios.

By Proactive Investors
December 21, 2022

Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, whi

By Proactive Investors
December 5, 2022

Zynerba Pharmaceuticals announces positive long-term data from Phase 2 INSPIRE trial at annual meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacolog

By Proactive Investors
November 28, 2022

Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trial

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that Fragile X patients treated with Zygel showed a significant reduction in behavioral symptoms c

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.